

## Supplemental material

### Supplementation with *Tribulus terrestris* extract exhibits protective effects on MCAO rats via modulating inflammation-related metabolic and signaling pathways

Hongming Zhang <sup>a, #</sup>, Wenjun Guo <sup>a, b, #</sup>, Xingxing Li <sup>a</sup>, Shengxu Xie <sup>a</sup>, Yue Liu <sup>a</sup>, Geng Chen <sup>d</sup>, Yang Wang <sup>c, \*</sup>, Yajuan Xu <sup>a, \*</sup>

- a. Key Laboratory of Medicinal Materials, Jilin Academy of Chinese Medicine Sciences, Changchun 130012, China
- b. School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China
- c. Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China
- d. The First Hospital of Jilin University, Changchun 130021, China

# These authors contributed equally to this study.

#### \* Corresponding Author

##### **Prof. Yang Wang**

Jilin Ginseng Academy,

Changchun University of Chinese Medicine, Changchun 130117, China

Tel.: +86-431-86763990

E-mail: wangyang@ccucm.edu.cn; wang.yang1986@hotmail.com

##### **Prof. Yajuan Xu**

Key Laboratory of Medicinal Materials,

Jilin Academy of Chinese Medicine Sciences, Changchun 130012, China.

Tel.: +86-431-86058628

E-mail: xyj6492@126.com

## 1 HPLC analysis of GSTTF

### 1.1 HPLC analysis

The separation of the GSTTF (1mg/mL) sample was conducted using an Agilent 1200 series LC system equipped with an Agilent ZorBax SB-C18 column (2.7  $\mu$ m, 4.6  $\times$  250 mm) at 25 °C with an injected volume of 10  $\mu$ L. The mobile phase consisted of acetonitrile (phase A) and water (phase B). It was carried out under the following gradient procedure: 0-5 min, 15-19%B; 5-30 min, 19-23%B; 30-50 min, 23-23.5%B; 50-55 min, 23.5-29%B; 55-70 min, 29-37%B; 70-90 min, 37-73%B; 90~100 min, 73-80%B. The chromatogram was monitored by an ELSD.

### 1.2 Results of HPLC analysis

The HPLC chromatogram of GSTTF was shown in **Figure S1**. By comparing the retention times with reference standards, we identified nine peaks as 26-O- $\beta$ -D-glucopyranosyl-(25S)-5 $\alpha$ -furostan-12-one-2 $\alpha$ ,3 $\beta$ ,22 $\alpha$ ,26-tetraol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 1**), 26-O- $\beta$ -D-glucopyranosyl-(25S)-5 $\alpha$ -furostan-12-one-3 $\beta$ ,22 $\alpha$ ,26-triol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 2**), 26-O- $\beta$ -D-glucopyranosyl-(25R)-5 $\alpha$ -furostan-12-one-3 $\beta$ ,22 $\alpha$ ,26-triol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 3**), 26-O- $\beta$ -D-glucopyranosyl-(25S)-5 $\alpha$ -furostan-20(22)-en-2 $\alpha$ ,3 $\beta$ ,26-triol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 4**), 26-O- $\beta$ -D-glucopyranosyl-(25R)-5 $\alpha$ -furostan-20(22)-en-12-one-2 $\alpha$ ,3 $\beta$ ,26-triol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 5**), 26-O- $\beta$ -D-glucopyranosyl-(25R)-5 $\alpha$ -furostan-20(22)-en-12-one-3 $\beta$ ,26-diol-3-O- $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 6**), 26-O- $\beta$ -D-glucopyranosyl-(25S)-5 $\alpha$ -furostan-20(22)-en-12-one-3 $\beta$ ,26-diol-3-O- $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 7**), 26-O- $\beta$ -D-glucopyranosyl-(25S)-5 $\alpha$ -furostan-20(22)-en-12-one-2 $\alpha$ ,3 $\beta$ ,26-triol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 8**), and 26-O- $\beta$ -D-glucopyranosyl-(25S)-5 $\alpha$ -furostan-20(22)-en-12-one-2 $\alpha$ ,3 $\beta$ ,26-triol-3-O- $\beta$ -D-glucopyranosyl(1 $\rightarrow$ 4)- $\beta$ -D-galactopyranoside (**peak 9**).

## 2 Animal and treatments

### 2.1 MCAO model establishment

The MCAO surgery was performed following the previous report with modifications [1]. Briefly, after rats were anesthetized, a 1 cm long midline skin incision was made on

the neck; then, the muscle on either side of the trachea was separated to expose the common carotid artery (CCA), the internal carotid artery (ICA), and the external carotid artery (ECA). Then a silicone-coated suture was inserted from the left ECA into the lumen of the ICA to occlude the origin of the MCA. The rats in the sham-operated group were subjected to an identical procedure without ligation. All animals were maintained at 25-28 °C during the surgery.

## **2.2 Infarct volume measurement**

The brains were removed and sliced into 2 mm thick coronal sections and stained with 2,3,5-triphenyltetrazolium chloride (TTC, 2% TTC in phosphate-buffered saline). All coronal slices were digitalized, and the area of cerebral damage was analyzed using Image-J software (National Institutes of Health, Bethesda, MD, USA).

## **2.3 Evaluation of neurological defects**

Neurological functional deficiency scores were following Longa's five-point scale[1]: zero points: no neurobehavioral dysfunction; one point: failure to flex the contralateral front limb completely; two points: circling counter-clockwise; three points: turning around to the affected side seriously; four points: cannot walk spontaneously. The higher the score, the more serious the impairment of animal behavior.

## **3 LC-MS-based metabolomics analysis**

### **3.1 Brain tissue extraction**

Sample preparation was performed according to our previous report[2]. An 80 mg brain tissue sample was homogenized with 1.5 mL prechilled methanol/water (v/v 1:1), then the obtained mixture was centrifuged at 15000 g for 15 min at 4 °C. The supernatant aqueous extracts were transferred into a centrifuge tube and were lyophilized with a freeze dryer. The retained pellet was extracted with a 1.6 mL prechilled dichloromethane/methanol (v/v 3:1) solution. After homogenization, the sample was centrifuged at 15000 g for 15 min at 4 °C, and the supernatant organic extracts were transferred into a centrifuge tube and were lyophilized with a freeze dryer. The aqueous and organic extracts were reconstituted in 120 µL of methanol/water (v/v 1:1), respectively, and centrifuged at 15000 g for 10 min at 4 °C. An aliquot of 5 µL supernatant was used for LC-MS analysis. The pooled aqueous and organic quality control (QC) sample was prepared by mixing an equal mass of each sample and prepared by the above procedures to perform method validation.


### **3.2 LC-MS condition**

The brain tissue extract was analyzed by a Vanquish Duo UHPLC coupled with a Q-


Orbitrap mass spectrometer equipped with an electrospray ionization (ESI) source (Thermo Fisher Scientific, San Jose, CA, USA). The aqueous extract was separated on an ACQUITY HSS T3 column (2.1 mm×100 mm, 1.8 μm) with a column temperature of 50 °C and an injection volume of 5 μL. The mobile phases are 0.1 % formic acid in water (mobile phase A) and 0.1% formic acid in methanol (mobile phase B). The gradient, at 0.4 mL/min, was 0.1%B (0-2 min); 0.1-25%B (2-6 min); 25-80%B (6-10 min); 80-90%B (10-12 min); 90-99.9%B (12-21 min); 99.9%B (21-23 min); 99.9-0.1%B (23-30 min), 0.1%B (30-35 min).

For the organic extract, the chromatographic separation was conducted on an Hypersil GOLD™ column (2.1 mm × 50 mm, 1.9 μm) at 50 °C, with an injection volume of 5 μL. The mobile phase consisted of 0.1% aqueous formic acid (phase A) and methanol containing 0.1% formic acid (phase B) under the following gradient program: 40%B (0-1 min) 40-70%B (1-6 min); 70%B (6-10 min); 70-80%B (10-15 min); 80%B (15-17 min); 80-91%B (17-18 min); 91-99.9%B (18-29 min); 99.9%B (29-32 min); 75-40%B (33-34 min) 40%B (34-35 min) with a flow rate of 0.4 mL/min.


The mass spectrometer was operated in both positive and negative ion modes, and the profile data was recorded in the range of  $m/z$  100-1500. The full scan acquisition was performed at the resolution of 35000, while the tandem MS information was acquired under ddMS2 (TOP 10) mode with a resolution of 17500, and the ramped normalized collision energy of 25-45. The key parameters of the ionization source were set as follows: capillary voltage of 3.5 kV in positive ion mode or -3.2 kV in negative ion mode, sheath gas flow 50 arb, auxiliary gas flow 15 arb, sweep gas flow 2 arb, capillary temperature 300 °C. Before sample analysis, the mass spectrometer was calibrated using the vendor-provided Pierce™ calibration solution (Thermo Fisher Scientific, San Jose CA, USA). All samples were maintained at 4 °C through the analysis.




**Figure S1** HPLC chromatograms of GSTTF (A), and the chromatograms of 9 standard references (B).



**Figure S2** The base peak chromatograms of QC sample from aqueous (A, ESI+, and C, ESI-) and organic extracts (B, ESI+, and D, ESI-).



**Figure S3** The representative BPC of aqueous brain tissue extract in three groups acquired in positive ion mode (A-C) and negative ion mode (D-F).



**Figure S4** The representative BPC of organic brain tissue extract in three groups acquired in positive ion mode (A-C) and negative ion mode (D-F).

## References

1. Longa, E.Z.; Weinstein, P.R.; Carlson, S.; Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke* **1989**, *20*, 84-91.
2. Wang, Y.; Guo, W.; Xie, S.; Liu, Y.; Xu, D.; Chen, G.; Xu, Y. Multi-omics analysis of brain tissue metabolome and proteome reveals the protective effect of ginsenosides of *Tribulus terrestris* L. fruit against ischemic stroke in rat. *J. Ethnopharmacol.* **2021**, *278*, 114280.